Transdifferentiating Liver Cells Into Beta Cells Using Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for treating insulin-dependent diabetes mellitus (IDDM) are inadequate due to low availability of donor tissue, variability in islet isolation, enzymatic and physical damage during isolation, and issues with immune rejection and xenotransplantation, necessitating the development of alternative procedures for isolating and transdifferentiating non-pancreatic cells to produce functional pancreatic beta cells.
Innovation Solution
An in vitro method involving the sequential administration of specific transcription factors (PDX-1, Pax-4, and MafA) to adult mammalian liver cells enriched for transdifferentiation, such as those with active Wnt-signaling pathways or activated glutamine synthetase response elements, to induce a pancreatic beta cell-like phenotype and function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If islet or pancreas fragment transplantation is used to replace insulin, then permanent insulin replacement is achieved, but low availability of donor tissue and variability in islet isolation occur
Solution Approach 1:
The patent uses liver cells as an intermediary substrate to produce insulin instead of directly transplanting pancreatic islets. Liver cells are transplanted into the liver, where they differentiate into insulin-producing cells, thereby mediating the insulin replacement function while avoiding the limitations of donor islet availability
Solution Approach 2:
The patent creates a copy of the insulin-producing function by introducing pancreatic transcription factors (PDX-1, Pax-4, MafA) into liver cells, causing them to replicate beta-cell characteristics and insulin secretion capabilities without requiring actual pancreatic islet transplantation
2Quantity of substance
If islet isolation is performed to obtain transplant material, then insulin-producing cells are obtained, but enzymatic and physical damage occurs during isolation
Solution Approach 1:
Instead of isolating pancreatic islets from the pancreas (traditional approach), the patent inverts the approach by transplanting liver cells into the liver and inducing them to become insulin-producing cells in situ, thereby avoiding the damaging isolation process entirely
Solution Approach 2:
The liver cells serve themselves by differentiating into insulin-producing cells after transplantation, utilizing the liver environment and introduced transcription factors to autonomously generate the desired functional cells without requiring external isolation or manipulation
3Reliability
If conventional islet transplantation is used, then insulin replacement is achieved, but immune rejection and xenotransplantation concerns occur
Solution Approach 1:
The patent creates functional copies of beta cells by inducing liver cells to express pancreatic transcription factors and acquire insulin-producing characteristics, thereby replicating the desired function while using autologous liver cells that are less immunogenic than allogeneic pancreatic islets
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method significantly increases the efficiency of producing transdifferentiated cells with pancreatic beta cell-like characteristics, including increased insulin production and glucose-regulated insulin secretion, overcoming the limitations of existing treatments for IDDM.
Implementation Method 1
isolating liver cells with an active Wnt-signaling pathway
Implementation Method 2
isolating liver cells with an activated glutamine synthetase response element (GSRE)
Implementation Method 3
contacting the enriched adult mammalian liver cell population with a pancreatic and duodenal homeobox (PDX-1) polypeptide or a nucleic acid encoding a pancreatic and duodenal homeobox (PDX-1) polypeptide
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3A~3E
AI summary
The present invention provides methods for the sequential and temporally-regulated administration of pancreatic transcription factors to induce non-pancreatic cells to transdifferentiate and mature along the pancreatic β-cell lineage. The present invention also provides methods for identifying, isolating and enriching transdifferentiation predisposed cells and methods for treating a degenerative pancreatic disorder such as diabetes.